Study #2024-0396
Phase II study of Asciminib for second-line treatment of chronic phase chronic myeloid leukemia
MD Anderson Study Status
Enrolling
Treatment Agent
Asciminib
Description
This is an open label, phase 2 study investigating asciminib in patients previously treated with one line of TKI therapy.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Malignant Solid Tumors
Study phase:
Phase II
Physician name:
Ghayas Issa
Department:
Leukemia
For general questions about clinical trials:
1-844-866-3603
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.